Why Stripe, PayPal, and Square Keep Shutting Down Peptide Merchants

Almost every peptide seller has the same story: a Stripe or PayPal account that worked fine for weeks or months, then got frozen overnight with a form-letter explanation and a fund hold that can run 90 to 180 days. It feels personal. It isn't. It's a classification problem, and understanding how the classification works is the difference between getting blindsided once and building around it permanently.

It starts with a merchant category code

Every business that accepts card payments gets tagged with a Merchant Category Code, or MCC — a four-digit number that tells card networks and processors what kind of business they're underwriting. Peptides don't have a clean code of their own, so they typically get swept into MCC 5122 (drugs, drug proprietaries, druggists' sundries) or a nutraceutical/supplement code — neither of which mainstream processors want on their books at scale. Once volume in one of those codes crosses an internal threshold, automated risk systems flag the account for review, and reviews for this category rarely end in your favor.

Chargebacks do the rest

Card networks track dispute ratios per merchant, and peptide sellers run structurally higher chargeback rates than most ecommerce categories — customers who don't recognize a billing descriptor, buyers disputing a purchase they don't want a partner to see, and a subset of genuinely dissatisfied customers with nowhere else to complain. Mastercard's Business Risk Assessment and Mitigation (BRAM) program exists specifically to catch merchants whose dispute ratio or business model crosses a defined risk line, and once you're flagged there, every acquirer downstream sees it.

The account isn't closed because your product is illegal. It's closed because the risk model decided your MCC, dispute ratio, or billing pattern costs more to keep than to drop.

What actually reduces the risk

• Clean billing descriptors. A descriptor that clearly matches your brand name and a support number cuts "I don't recognize this charge" disputes significantly — often the single largest chargeback category.
• Matching an acquirer's actual risk appetite. Specialist high-risk processors underwrite peptide merchants on purpose, at a price that reflects the real risk — not a mainstream processor's risk model that was never built for this category.
• Redundancy, not loyalty. A single-gateway setup means one termination is a business-ending event. Two or three gateways with tested failover means it's a bad Tuesday.
• Documentation before you need it. COAs, RUO labeling, and clear terms of sale are exactly what a processor asks for during a review — and having them ready is often the difference between a temporary hold and a permanent closure.

The real fix isn't a better processor. It's an architecture.

Every specialist processor eventually tightens its own risk model or gets acquired by one that does. The brands that keep selling through that churn are the ones that built checkout to survive a single processor failing — not the ones that found one good processor and stopped thinking about it. That's infrastructure work, not a one-time vendor decision, and it's the first thing we look at in every audit. If you're dealing with a freeze right now rather than planning ahead of one, start with what to do in the first 48 hours.